Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Receivables (2018 - 2025)

Exagen (XGN) has disclosed Receivables for 8 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 39.12% year-over-year to $10.9 million, compared with a TTM value of $10.9 million through Dec 2025, up 39.12%, and an annual FY2025 reading of $10.9 million, up 39.12% over the prior year.
  • Receivables was $10.9 million for Q4 2025 at Exagen, down from $11.1 million in the prior quarter.
  • Across five years, Receivables topped out at $17.0 million in Q3 2023 and bottomed at $6.1 million in Q4 2022.
  • Average Receivables over 5 years is $10.7 million, with a median of $10.2 million recorded in 2021.
  • The sharpest move saw Receivables soared 69.29% in 2023, then tumbled 44.92% in 2024.
  • Year by year, Receivables stood at $9.7 million in 2021, then tumbled by 37.11% to $6.1 million in 2022, then grew by 8.2% to $6.6 million in 2023, then rose by 18.71% to $7.8 million in 2024, then surged by 39.12% to $10.9 million in 2025.
  • Business Quant data shows Receivables for XGN at $10.9 million in Q4 2025, $11.1 million in Q3 2025, and $14.3 million in Q2 2025.